REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design-MedSci.cn

REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

Ghorani, E; Quartagno, M; Blackhall, F; Gilbert, DC; O'Brien, MER; Ottensmeier, CHH; Pizzo, E; Spicer, J; Williams, A; Badman, P; Milner-Watts, C; Parmar, MK; Seckl, MJ

ANNALS OF ONCOLOGY, 2023; 34 ():

科室
- - 订阅+
  - 更多科室
工具
服务